Noida, UP -- (SBWIRE) -- 11/17/2014 -- According to the National Cancer Institute’s estimates, nearly 142,820 people would be diagnosed with and 50,830 would die of cancer of the colon and rectum in 2013. On the other hand, it is estimated that 232,340 women would be diagnosed with and 39,620 women would die of cancer of the breast in 2013. Moving in the same lines, USFDA approved the first generic version of Xeloda (capecitabine), an oral chemotherapy pill used to treat cancer of the colon or rectum (colorectal cancer) that has spread to other parts of the body (metastatic) as well as metastatic breast cancer. Teva Pharmaceuticals USA has gained FDA approval to market the generic capecitabine in 150 and 500 mg strengths.

Recently, India based drug firm Dr Reddy’s Laboratories launched its generic Decitabine injection in the strength of 50 mg in the US market following approval by the USFDA. The company's product is the generic version of Dacogen. Dacogen is used in the treatment of myelodysplastic syndromes and for acute myeloid leukemia.

Holistically our latest research report “Global Cancer Generics Market Outlook 2018”, elicits the global oncology market and global caner generics market, cancer incidences are discussed providing an insight about the geographical share and country wise incidence rate. Furthermore, the generic cancer drugs are scrutinized according to their dosage form. In addition to that, the cancer generics industry with respect to the major indications is also discussed in depth, emphasis on current and future incidence, regional analysis and the patent expiration status of key cancer drugs.

Analysis of key industry trends and drivers crucial to the market is also added. Moreover, the dossier also contains the analysis of the top notch global cancer generics manufacturers. On the holistic basis, the report is primarily inclined towards the in-depth study of global cancer generics market, asserting the fact that Cancer Generics is going to be the focus area for several industry players, thereby labeling Cancer Generics as a field with substantial growth potential over the next few years.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM704.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.